AlphAIAlphAI — Financial news for AI agents
benzinga.comSEP 152 min read$AZN

AstraZeneca, Leidos, Expeditors International: CNBC ‘Final Trades’ - Expeditors International (NYSE:EXPD)

CNBC's 'Final Trades' featured picks from Jim Lebenthal (AstraZeneca, AZN), Stephen Weiss (Leidos, LDOS), Liz Thomas (Treasuries), and Joseph Terranova (Expeditors, EXPD). AZN reported regulatory approvals and strong trial data, LDOS beat Q2 estimates and raised guidance, and EXPD also exceeded Q2 expectations. Shares of AZN, LDOS, and EXPD rose 2.3%, 3.1%, and 0.5% respectively on Monday.

Original reporting
benzinga.com
Published Sep 15, 2026, 11:39 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 6:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$AZN
Bullish
high confidence
Mentioned
$AZN · $LDOS · $EXPD
Relevance
8/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$AZNBullishHigh
01

Why it matters

New earnings numbers and drug approval constitute primary disclosures that can move prices today.

02

Market read

Fresh earnings and regulatory news provide actionable trading signals across pharma, defense, and logistics sectors.

03

What to watch

Potential regulatory scrutiny on AstraZeneca's new therapy and macro‑economic headwinds for logistics.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

The article summarizes final trade picks from a CNBC segment, highlighting fresh earnings beats and a regulatory approval.

Company-level read

Ticker impact

$AZNBullishHigh confidence
Context

AstraZeneca secured regulatory approval for a new breast cancer treatment and reported strong Phase 3 trial data.

Expected impact

upward pressure in near term

Evidence & confidence

Approval and data are fresh, material catalysts for a large pharma.

$LDOSBullishHigh confidence
Context

Leidos posted better‑than‑expected Q2 earnings and raised FY26 guidance.

Expected impact

upward move expected

Evidence & confidence

First report of earnings numbers and guidance change.

$EXPDBullishHigh confidence
Context

Expeditors International reported Q2 earnings beat and higher sales.

Expected impact

slight upside

Evidence & confidence

Fresh earnings data for a logistics firm.

Market effects

Sector

Pharma approval may lift biotech peers; defense and logistics earnings could influence sector sentiment.

Regional

European pharma news adds upside to UK/European markets; US earnings affect broader market.

Global

Combined earnings and regulatory news provide cross‑sector momentum.

Counterpoint

What could challenge this read

If earnings guidance is overly optimistic, stocks could face pull‑back on profit‑taking.

Key entities

  • Company
    AstraZeneca

    Pharmaceutical firm with new breast cancer drug approval.

  • Company
    Leidos Holdings

    Defense contractor reporting earnings beat.

  • Company
    Expeditors International

    Logistics provider with earnings beat.

Read at source← All news

Related articles

SEP 17
$AZNMed

AstraZeneca Gains as Enhertu Clears England's Value Gate

AstraZeneca's Enhertu gained NHS approval in England for HER2-low metastatic breast cancer treatment, reversing a prior rejection. The company's shares rose 1.3% to $165.04. The drug's cost-effectiveness was not disclosed, but it extends survival by around six months. This approval may expand access in Wales and Northern Ireland, potentially boosting AstraZeneca's revenue.

tradingview.com2 min
SEP 17
$AZNHighAI 9/10

AstraZeneca (AZN) Wins FDA Approval for its Breast Cancer Pill After Regulators Voiced Doubts

AstraZeneca (AZN) received FDA accelerated approval for its breast cancer drug, Etcamah, despite earlier regulatory doubts. The drug, used with a CDK4/6 inhibitor, showed a 56% reduction in disease progression or death in a Phase III trial. AstraZeneca must complete confirmatory studies to maintain approval. The drug is projected to achieve over $5 billion in peak annual sales.

insidermonkey.com2 min
SEP 17
$AZNHighAI 8/10

AstraZeneca-Daiichi get nod for NHS to use breast cancer drug in England

AstraZeneca and Daiichi Sankyo announced that their breast cancer drug, Enhertu, has been approved for use in England's NHS, following a previous rejection. The approval, based on 2022 trial data, allows reimbursement for HER2-low metastatic breast cancer patients. The companies aim to seek approval in Wales and Northern Ireland next. About 1,000 women annually may benefit from the treatment, which has a list price of £1,455 per 100mg vial in the UK.

sowetan.co.za2 min
SEP 17
$AZNMed

NICE U-Turn Brings Life-Extending Therapy to NHS Patients

NICE approved Enhertu (trastuzumab deruxtecan) for NHS use in England for 1,000 HER2-low advanced breast cancer patients, reversing a 2024 cost-effectiveness rejection. The drug, made by Daiichi Sankyo and AstraZeneca, extends survival to ~2 years vs. 17.5 months with chemotherapy. A commercial deal enabled the approval.

medscape.com2 min
SEP 17
$AZNMedAI 8/10

First-Line Enhertu Delayed HER2-Mutant Lung Cancer Progression by Six Months Over Keytruda Plus Chemotherapy, but Survival Remains Unsettled

Enhertu (trastuzumab deruxtecan) delayed cancer progression in HER2-mutant lung cancer patients by 6 months vs. Keytruda plus chemotherapy, per the DESTINY-Lung04 trial. Enhertu reduced progression/death risk by 37%, but survival data is inconclusive. AstraZeneca and Daiichi Sankyo, which co-develop the drug, presented the results at a medical conference. Enhertu is not yet FDA-approved for first-line treatment of this cancer.

medicaldaily.com3 min